Distraction Osteogenesis Devices Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Market Scenario:
Global Distraction Osteogenesis Devices Market is expected to grow significantly over the forecast period. Distraction osteogenesis is the biological process of the new bone formation between bone segments which are gradually separated by incremental traction.
Numerous factors such as advancements in distractor devices such as miniaturized internal and external devices, easily placeable and easy handling are expected to drive the growth of the market. For instance, In May 2018, DePuy Synthes, a part of the Johnson & Johnson Medical Devices Companies, announced an exclusive agreement in the US between DePuy Synthes Sales, Inc. and Prosidyan to promote the Fibergraft family of products, a line of synthetic bone graft materials which are ultra-porous, designed for ease of use, and have been engineered for ideal resorption in clinical use during spine fusion surgery. By adding Fibergraft to its offerings, DePuy Synthes will further enhance the company’s portfolio of biomaterials and distractors.
Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6392
Moreover, various risks such as failure to follow the distraction protocol and damages to nerves hamper the market growth during the assessment period.
Key players
Johnson & Johnson Services, Inc., Zimmer Biomet Holdings, Inc., Stryker Corporation, KLS Martin Group, Osteomed, Acumed LLC, Jeil Medical Corporation, Ningbo Cibei Medical Treatment Appliance Co., Ltd. Ortho Max Manufacturing Company Pvt. Ltd., Ortho Care and Titamed are some of the key players in the global distraction osteogenesis devices market.
Segmentation
The Global Distraction Osteogenesis Devices Market has been segmented into device type, age, application, and end-user.
The market, based on device type, has been segmented into mandibular distraction devices, palatal distraction devices, alveolar distraction devices, craniofacial distraction devices, Lefort distraction devices, small bone distraction devices, and others. The market, based on craniofacial distraction devices, has been further segmented into external and internal distractors. The market, based on external distractors is further classified into unidirectional distractors, bidirectional distractors, and multiplanar distractors whereas the market, based on, internal distractors can be classified into tooth-borne distractors, bone-borne distractors, and hybrid distractors. The market, by age, has been segmented into pediatrics and adults. The market, by application, has been segmented into dentistry, podiatry, orthopedics, and others. The market, by end-user, has been segmented into hospitals, orthopedic clinics, and others.
Regional Market Summary
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Distraction Osteogenesis Devices Market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European distraction osteogenesis devices market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The Distraction Osteogenesis Devices Market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The distraction osteogenesis devices market in the Middle East & Africa has been segmented into the Middle East and Africa.
Geographically, North America is expected to dominate the global distraction osteogenesis devices market owing to increasing number of procedures for treating facial abnormalities in the US. Also, most of the key players have their research and development teams working in this field in the US which in turn increases the awareness among the people about the technique in this region.
The European market is expected to be the second-largest due to increase in initiatives taken by public and private organizations in this field.
Browse Complete 90 Pages Premium Research Report Enabled with 94 Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/distraction-osteogenesis-devices-market-6392

Cardiopulmonary Disease Diagnostics and Treatment Market Professional Survey about Therapeutics and Pipeline Review 2019

Market Scenario:

Thecardiopulmonary disease is a general term used to describe a variety of different diseases and conditions related to heart and lungs. Cardio Vascular Disease is a complex disease with a wide variety of risk factors including those that are modifiable, such as physical inactivity, non-modifiable factors such as age, genes, congenital dispositions, and gender. Respiratory disease is a medical term that includes extreme conditions affecting the organs and tissues which make gas exchange possible in higher organisms. Depending upon the type of cardiopulmonary disease present the treatment options vary and may include changes in diet or lifestyle, use of medications issued on prescription or surgery. The most common cardiopulmonary diseases are hypertension, stroke, and coronary heart disease. Untreated, cardiopulmonary diseases can be deadly. Cardiopulmonary diseases are the major cause of death globally.

The substantial growth in the frequency of health conditions related to the lungs and heart is the key factor to boosts the growth of this market. Also, the increase in aged population and the rising frequency in cardiovascular and respiratory diseases is also anticipated to drive the global market over the forecast period. Exposure to nicotine, tobacco products, and others increases the risk of obtaining cardiopulmonary diseases.

Increase in the rise of advanced technological equipment for diagnosing the disease will drive market rate exponentially. However, the huge cost of treatment and the regulatory nature of government on pharmaceutical companies will hamper the growth of the market.

Key Players

• Cardinal Health
• Cosmed Medical
• GE Healthcare
• Halma plc
• Hill-Rom Holdings, Inc.
• Koninklijke Philips N.V.
• MGC Diagnostics Corporation
• NIHON KOHDEN CORPORATION
• Schiller AG
• Masimo Corporation
• Vyaire Medical Inc

Segmentation

The global cardiopulmonary disease diagnostics and treatment market has been segmented on the basis of disease type, type, and end-user.

On the basis of disease type, the market has been classified as cardiovascular and respiratory diseases. The cardiovascular diseases are segmented into coronary artery disease, angina pectoris, myocardial infarction, dysrhythmia, hypertension, and others. The respiratory diseases are segmented into influenza, asthma, bronchitis, emphysema, cystic fibrosis, and others.

On the basis of end users, the market has been classified as hospitals, clinics, diagnostic centers, specialty clinics and rehab centers, research institutes and others.

On the basis of region, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The Americas has been further segmented into North America and South America, with the North American market divided into the US and Canada.

On the basis of type, the market has been classified as diagnosis and treatment. The diagnosis market is segmented into an electrocardiogram (ECG), Holter monitoring, echocardiogram, stress test, cardiac catheterization, cardiac computerized tomography (CT) scan, cardiac magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), stress blood pressure monitors, pulse oximeters and spirometry. The treatment market is segmented into medications. The medications segment is further sub-segmented into angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBS), anticoagulants, antiplatelet agents and others.

The European cardiopulmonary disease diagnostics and treatment market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

The cardiopulmonary disease diagnostics and treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The cardiopulmonary disease diagnostics and treatment market in the Middle East and Africa has been segmented into the Middle East and Africa.

Regional Market Summary

In the cardiopulmonary disease diagnostics and treatment market, North America is anticipated to account for the largest market share due to the early adoption of advanced medical technologies, the rise in awareness, the rise in growth of the healthcare sector, and due to favorable compensation setting for many surgical procedures.

 The European market is expected to hold the second largest market share. The market growth in this region can be attributed to rising frequency of cardiovascular disorders, increasing number of surgeries and increasing demand for advanced treatment procedures are boosting the European market.

The market share in Asia-Pacific is also projected to experience growth in the near future due to access to optimal treatment facilities and growing demand for advanced technology, better adoption rate, increase in disposable income, and rising medical tourism.

The market in the Middle East and Africa is expected to account for the smallest share of the global cardiopulmonary disease diagnostics and treatment market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report        

Verrucous Carcinoma Market 2019 Global– Key Players, Size, Trends, Growth- Analysis To 2023

Global Verrucous Carcinoma Market Research Report, by Diagnosis (Biopsy, Endoscopy, Imaging Tests), Treatment (Radiation Therapy, Chemotherapy), End-User (Hospitals and Clinics, Ambulatory Surgical Centers, Diagnostic Centers) – Global Forecast Till 2023

Market Insights

Verrucous Carcinoma typically debuts as an anomalous growth or as alteration in the constancy of an earlier potentially malignant ailment of the oral cavity. Verrucous Carcinoma is a rare, locally aggressive, clinically exophytic, low-grade, slow-growing, well-differentiated squamous cell carcinoma with nominal metastatic potential. It is unusual subtype of malignant ailment which affects oral cavity. Verrucous Carcinoma can affect all mucosal sites of the oral cavity. However, the frequency of malignant transformation of a leukoplakia to an OVC is considerably higher if they are in the gums in comparison to the tongue.

Verrucous Carcinoma is mainly caused by the snuffing of tobacco or chewing of tobacco. It is also referred to as snuff dipper's cancer. Verrucous Carcinoma mostly prevails at oral zones. The condition common in males within the age group 50 to 80 years. The increasing incidences of oral cancer primarily influences the market. Lifestyle factors such as smoking marijuana or tobacco and alcohol consumption mostly drives the Verrucous Carcinoma market. Additionally, growing consumption of alcohol, increasing adoption of sedentary lifestyle, increasing rates of sexually transmitted viruses by human papillomavirus, and family history of cancer prevalence contribute largely towards the development of the market. In 2015, the World Health Organization reported that 1.1 billion people smoked tobacco globally. This is likely to accelerate the market growth over the forecast period.

However, the high cost of surgical procedures, side effects associated with treatments, and expensive chemotherapy treatments are anticipated to limit the market growth to a certain extent.

Market Segmentation

The worldwide Verrucous Carcinoma market has been segmented based on treatment, end-user, and diagnosis.

Based on treatment, the Verrucous Carcinoma market has been segmented into radiation therapy, surgery, targeted drug therapy, and chemotherapy. Surgery has been sub-segmented into Mohs micrographic surgery and surgical excision. Chemotherapy has been sub-segmented into 5-fluorouracil, bleomycin, methotrexate, cisplatin, and others. Based on end-user, the Verrucous Carcinoma market has been segmented into ambulatory surgical centers, hospitals and clinics, research centers, diagnostic centers, and others. Based on diagnosis, the Verrucous Carcinoma market has been segmented into endoscopy, imaging tests, and biopsy. Imaging tests have been sub-segmented into magnetic resonance imaging, positron emission tomography scans, and computerized tomography scans.

Regional Analysis

The Americas represent the largest share in the global Verrucous Carcinoma market. The market growth is owing to the increasing healthcare expenditure and surging prevalence of Human Papillomavirus (HPV). As recorded by the Genital HPV Infection, Fact Sheet 2017, 79 million American adults were infested with HPV. Europe (Belgium, UK, Netherlands, and France) represents the second largest Verrucous Carcinoma market over the forecast period. Rising prevalence of head and neck cancer drives the Verrucous Carcinoma market in this region. The Cancer Research UK revealed that in 2015, there were12061 new instances of neck and head cancer. These statistics substantially drive the Verrucous Carcinoma market in Europe.

In 2017, Asia-Pacific was estimated to be the fastest growing region for the worldwide Verrucous Carcinoma market. The market has been expected to develop owing to the rising addiction to smoking. According to the World Health Organization, in 2015, 33.7% and 47.6% of people smoked tobacco in Japan and China, respectively. The Middle East and Africa holds the least market share due to lack of availability of trained healthcare professionals and low per capita income in the region. Nevertheless, the growing palliative and oncology care services both at the community and the hospital level are expected to influence the market positively.

Key Players

The global Verrucous Carcinoma market is dominated by key players such as Qilu Pharmaceutical Co., Ltd. (Asia Pacific), Bristol-Myers Squibb Company (US), Eli Lilly and Company. (US), Teva Pharmaceutical Industries Ltd. (Israel), Merck & Co., Inc. (US), F. Hoffmann-La Roche Ltd (Europe), Pfizer Inc. (US), Novartis AG (Europe), and others.

Browse more Life Sciences Reports @ https://www.marketresearchfuture.com/categories/life-sciences-market-report

Healthcare Asset Management Market to Observe Strong Development by 2019

Healthcare Asset Management Market: Information, Product (Radiofrequency Identification (RFID) Devices, and Others), Application (Hospital Asset Management and Others), End-User (Hospital, Laboratory, Pharmaceutical, and Others)–Global Forecast Till 2023

Market Scenario

The healthcare asset management market to showcase an extraordinary 18.2% CAGR over the forecast period (2018-2023), revealed Market Research Future (MRFR) in a well-outlined report on the same market.

The healthcare asset management includes patient record management, easy access to maintenance record, locating medical equipment, and registering of the status of each equipment. Increasing demand for healthcare and the availability of varying types of treatment are creating a situation where easy access to everything is prized. This would help in quick and efficient service delivery to patients. When time is of the essence, then keeping everything at a hand’s distance becomes necessary. Healthcare asset management does that quite efficiently. MRFR, while having a detailed study of the healthcare asset management market, harps on segments and their volume-wise and value-wise valuation. In sync, it also analyses the factors that may play an important role in the coming years.

Patient safety gets the priority in the healthcare sector which can provide the much-needed traction to the market. Among the other factors, its ability to simplify the work process can be considered one of the major influencers. In addition, with rising investment in R & D, the sector is only going to flourish. However, accuracy issues and high installation cost can hamper the expected growth rate of the market.

Key Players

• cenTrak,
• Airista Flow,
• GE Healthcare,
• IBM Corporation,
• Infor Inc.,
• Tyco Security Products.,
• Intelligent InSites,
• Motorola Solutions, Inc.,
• Radianse, JADAK (a Novanta Company),
• Siemens Healthineers, Sonitor Technologies,
• Stanley Black & Decker, Inc.,
• Ekahau, Inc.

Segmentation

The healthcare asset management market has been segmented on the basis of product, application, and end-user.

On the basis of product, the market has been classified as real-time location systems (RTLS), radiofrequency identification (RFID) devices and ultrasound & infrared tags. The real-time location systems (RTLS) segment has been further divided into hardware, software and services. The hardware segment has been further divided into tags/badges and readers/interrogators.

The radiofrequency identification (RFID) devices have been classified as hardware, and software and services. the hardware segment has been divided tags, readers/interrogators, and accessories. The tags sub-segment has been segmented into passive tags and active tags. The passive tags segment has been divided into high-frequency (HF) tags, ultra-high-frequency (UHF) tags and low-frequency (LF) tags. Furthermore, the application segment has been sub-segmented into hospital asset management and pharmaceutical asset management. The hospital asset management segment includes equipment tracking and management, patient management, temperature and humidity monitoring, staff management and infection control and hand hygiene compliance. The pharmaceutical asset management segment includes drug anti-counterfeiting and supply chain management.

The market, by end-user, has been segmented into Hospital/Clinic, Laboratories, Pharmaceutical companies, Biotechnology.

The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The healthcare asset management market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.

The healthcare asset management market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The healthcare asset management market in the Middle East & Africa has been segmented into the Middle East and Africa.

The European healthcare asset management market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. 

Regional Summary

MRFR included regions such as the Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) in their report on the healthcare asset management market.

The Americas is a market that is highly evolved, both infrastructurally and technologically. High investment potential in the region enables various end-users in integrating the healthcare asset management market. These factors are going to play a big role in maintaining the premier position it is enjoying now in the global market.

Europe’s market is the second biggest one where the crisis of counterfeit drugs can be avoided with such effective methods. At the same time, the increasing investment for research and development sector can assure the market of better management technology in the coming years. The regional healthcare sector is relying much on the prosperity of healthcare asset management as it can ease the entire workflow to back the growing demands from patients. The AAPC market is all set to grow with the fastest CAGR during the forecast period. Rapid digitization in the healthcare sector is expected to boost the market. The MEA market can contribute a small part only as the region is technologically not that well-structured.

Browse more Healthcare IT Reports @

https://www.marketresearchfuture.com/categories/healthcare-it-market-report

Bone Implant Market Dynamics, Forecast, Analysis and Supply Demand 2019

“Bone Implant Market” Exclusive Analysis by  Future  by Biomaterial (Metal and Others), Product (Orthopedic Screws, Orthopedic Plates, and Others), Application (Hip Orthopedic Implants and Others), Device (External and Internal), and End-User–Global Forecast Till 2023

Market Scenario:

Bone implants are used to heal bone fractures or as fillers and scaffolds to facilitate the bone formation. Bone implants are surgically placed into the body and designed to restore the function by replacing or reinforcing a damaged structure. The rapid growth in aged population, increasing number of orthopedic surgeries, and rising occurrences of sports-related injuries are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by top players such as new product launches are contributing to the growth of the market. For instance, in May 2018, NN Inc. acquired Paragon Medical for USD 375 million. Paragon Medical is a medical device manufacturer which focuses on orthopedics, case and tray, and implant and instrument markets.  The acquisition supports NNs Inc.’s strategy to grow its life science revenue and positions NN Inc. as one of the ten largest contract manufacturers in orthopedics.

The rising cost of orthopedic surgeries, the high price of bone implant products, corrosion and instability of bioimplants, and stringent government policies may hinder the growth of the market during the assessment period.

The Global Bone Implant Market is expected to grow during the forecast period (2018–2023) at a CAGR ~6.8%.

Key Players

• Depuy Synthes Inc. (Johnson & Johnson),
• Globus Medical, Inc.,
• NuVasive, Inc.,
• Smith & Nephew plc. ,
• Stryker Corporation,
• Zimmer Biomet Holdings, Inc.,
• Integra LifeSciences Holdings Corporation,
• Medtronic, plc,
• The Orthopedic Implant Company,
• Wright Medical Group N.V.,
• Aesculap Implant Systems,
• BioTek Instruments, Inc.,
• Conmed Corporation,
• Arthrocare Corporation.

Segmentation

The global bone implant market has been segmented on the basis of biomaterial, product, application, device, and end-user.

On the basis of biomaterial, the market has been classified as metals, ceramics, and polymers. The metal segment has been further divided into titanium, stainless steel, cobalt chromium alloy, gold alloys, and Tantalum. The ceramics segment has been further divided into alumina, hydroxyapatite, beta-tricalcium, phosphate, carbon, bioglass, zirconia, and zirconia-toughened alumina. The polymers segment has been classified into polymethylmethacrylate, polytetrafluoroethylene, polyethylene, polysulfone, polyurethane, and polyether ether ketone.

The market, by products, is divided into orthopedic screws, orthopedic plates, interlocking nails (rods), and others. The market, by application, has been classified into hip orthopedic implants, knee orthopedic implants, spine orthopedic implants, dental orthopedic implants, and others.

The market, by device, is divided into external fixators and internal fixators.

The market, by end-user, has been segmented into orthopedic clinics, hospitals, and others.

Regional Market Summary

The Americas is likely to dominate the global bone implant market. The rising occurrence of osteoarthritis and osteoporosis in the aging population, increase in the number of surgical procedures, the presence of a well-established healthcare system, growing prevalence of sports injuries, and adoption of highly advanced technology are contributing to the growth of the market. According to the Annual Report of the American Joint Replacement Registry (AJRR), 860,080 hip and knee replacement procedures from 4,755 surgeons at 654 institutions were conducted in 2017.

Asia-Pacific is expected to be the fastest-growing bone implant market during the forecast period owing to the increasing prevalence of medical tourism, orthopedic diseases along with bone-related issues, and rising investments in healthcare and expansions by market players in the region. Asia-Pacific is anticipated to show significant growth from 2018 to 2023

The European market is expected to be the second-largest bone implant market. The market growth in this region can be attributed to the rising prevalence of orthopedic diseases. Moreover, the increasing demand for orthopedic implants and spinal treatment devices during the forecast period are contributing to the growth of the market in this region. Major players are adapting inorganic growth policies to expand their portfolio. For instance, Stryker Corporation, a major player in the orthopedic market acquired Vexim for USD 215 million in 2017. Vexim offers spine related products, which helped Stryker Corporation to capture the new segment.

The market in the Middle East and Africa is expected to account for the smallest share of the global bone implant market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.

Browse more Medical Devices Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report

Sacroiliitis Market, Segments, Growth and Value Chain 2019

Global Sacroiliitis Market Research Report, by Diagnosis (Imaging Tests and Anesthetic Injections), Treatment (Medications, Joint Injections, Joint Fusion, Radiofrequency Denervation), End-User (Hospitals, Diagnostic Centers) – Global Forecast Till 2023

Market Scenario

The Global Sacroiliitis Market is expected to witness tremendous growth during the forecast period. The growing prevalence of arthritis increase in traumatic injuries, growing prevalence of spondylitis, increased research on joint health and joint conditions, and adoption of technologically-advanced systems are the key factors for the market to grow. However, factors such as high cost of diagnostics and treatment and surgical procedures are expected to restrict the market growth during the forecast period.

According to the Centers for Disease Control and Prevention (2013to 2015), 22.7% Americans of the total population had arthritis, annually. Thus, such a high prevalence of arthritis and increasing government funding for the healthcare sector enhance the growth of this market.

However, factors such as expensive diagnostic tests and the high cost of surgical procedures are expected to restrict the market growth during the forecast period.

Key players

• Medacta International,
• SI-BONE,
• Globus Medical,
• Zyga Technology,
• Nutech Medical,
• CoorsTek Medical LLC,
• Aspen Medical Products,

Segmentation

The Global Sacroiliitis Market is segmented on the basis of diagnosis, treatment, and end-user. The sacroiliitis market, by diagnosis, is sub-segmented into imaging tests and anesthetic injections. The imaging tests category includes x-ray, MRI, and CT scan. On the basis of treatment, the market is categorized into medications, joint injections, radiofrequency denervation, electrical stimulation, joint fusion, facet block, chiropractic manipulation, and physical therapy. On the basis of end-user, the market is segmented into hospitals and clinics, pharmacies, and diagnostic centers.

On the basis of region, the global sacroiliitis market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.

The Americas is sub-segmented into North America and South America. The North American region is further segmented into the US and Canada. The European region is divided into two, namely, Western Europe and Eastern Europe. Western Europe is further classified into Germany, Italy, France, the UK, Spain, and the rest of Western Europe. The Asia-Pacific region is sub-segmented into Japan, China, India, Australia, the Republic of Korea, and the rest of Asia-Pacific. The Middle Eastern and African region is sub-segmented into the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, and the rest of the Middle East and Africa.

Regional Analysis

The Sacroiliitis Market is dominated by North America owing to the high prevalence of arthritis and high healthcare investments within this region. According to the Centers for Disease Control and Prevention by 2040, 78.4 million will have doctor-diagnosed arthritis.The rising adoption of technologically advanced systems for early diagnosis of diseases also drives the market growth in this region.

Asia-Pacific was projected to be the fastest growing region for the Global Sacroiliitis Market. Key factors such as the growing patient pool, the high prevalence of chronic diseases, developing healthcare infrastructure, and increasing research and development activities in the biotechnology sector influence the market in this region. The presence of major market players such as China, India, and Japan drives the market growth.

It is estimated that Europe stood second in the Global Sacroiliitis Market. The increasing prevalence of lower back disorders and the availability of minimally invasive surgical procedures for Sacroiliitis drive the market growth in this region. According to The European (2015), sacroiliac joint was the main reason for chronic low back pain in Europe.

The Middle East and Africa holds the least share of the Global Sacroiliitis Market due to the presence of stringent government policies and poor economies. However, growing awareness among the population, rising government initiatives to improve the healthcare sector, and high investments by private market players in this region can boost the market growth. 

Browse more Pharmaceutical Reports @ https://www.marketresearchfuture.com/categories/pharmaceutical-market-report

Colposcopy Market Volume Forecast and Value Chain Analysis 2019

Global Colposcopy Market Research Report: Instrument Type (Optical Colposcope, Digital Colposcope), Instrument Portability (Portable, Fixed, Handheld), Application (Cancer Screening, Examinations), Magnification Type, End-User – Global Forecast Till 2023

Market Scenario

A colposcope is basically a surgical instrument similar to an electric microscope with a source of light that allows gynecologists to examine the vagina and cervix more clearly and under proper magnification. The rising prevalence of cervical cancer around the globe is the primary factor driving the growth of the colposcopy market.

For instance, according to the World Health Organization (WHO) in 2017, cervical cancer is the second most reason for the death of women worldwide. Currently, awareness programmes are conducted by numerous NGOs focusing on health-related issues in women such as cervical cancer which will increase the demand for colposcopes.

The Global Colposcopy Market is expected to gain prominence over the forecast period (2018–2023). It is estimated that the global colposcopy market is expected to register a CAGR of ~6.8% during the forecast period, 2018–2023.

Despite these drivers, factors such as high installation cost of this device and lack of skilled clinical users to operate colposcopes are likely to restrain the growth of the market.

Company Profiles            

• Carl Zeiss
• Olympus Corporation
• Danaher Corporation
• Philips Healthcare
• CooperSurgical
• McKesson Corporation
• DYSIS Medical
• Atmos
• Alliton
• Seliga Microscopes
• Karl Kaps
• Bovie Medical

Segmentation

The global colposcopy market is segmented on the basis of instrument type, instrument portability, application, and end-users.

On the basis of instrument type, the market is classified into optical colposcopes and digital colposcopes.

On the basis of instrument portability, the market is classified into portable, fixed, and handheld.

On the basis of application, the market is classified as cervical cancer screening, physical examinations, and others.

On the basis of magnification type, the market is classified into fixed magnification and variable magnification

On the basis of end-user, the market is classified into hospitals, clinics, diagnostic centers, and others.

Geographically, the market has been segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa. The American colposcopy market is further segmented into North America and South America. North America is further classified as the US and Canada.

The European colposcopy market is segmented into Western Europe and Eastern Europe. Western Europe is further classified as Germany, France, the UK, Italy, Spain, and the Rest of Western Europe. 

The colposcopy market in Asia-Pacific is segmented into Japan, China, India, the Republic of Korea, Australia, and the Rest of Asia-Pacific.

The Middle Eastern and African colposcopy market is segmented into the Middle East and Africa.

Regional Market Summary

Asia-Pacific is the fastest growing region in the market owing to the increasing cases of cervical cancer in the region, growing demand for cervical cancer screening, and rising healthcare expenditure in Asian countries. Additionally, according to a study published in the World Health Organization (WHO) in 2017, every year cervical cancer kills more than 250000 women, and 85% of these deaths occur in low- and middle-income countries. Furthermore, the rapid development of economies and increasing healthcare expenditure have fuelled the growth of the market.

The Americas is likely to dominate the global colposcopy market owing to technological advancements in colposcopes such as high-quality video and improved accuracy in detection. For instance, the American Cancer Society in 2018, estimated about 13,240 new cases of invasive cervical cancer to be diagnosed in the US with nearly 4,170 women dying from cervical cancer. Furthermore, continuous development of advanced colposcopy by manufacturers in the region contributes to the market growth.

Europe is likely to hold the second position in the global colposcopy market. It is expected that the favorable reimbursement scenario is responsible for the ambient growth in this region. Additionally, according to the Cancer Research UK in 2017, more than 3000 new cases of cervical cancer are diagnosed in the UK each year.  

The Middle East and Africa accounts for the lowest market share in the global colposcopy market owing to the lack of awareness regarding cervical cancer in the MEA region.

Browse more Medical Device Reports @ https://www.marketresearchfuture.com/categories/medical-devices-market-report